Horizon Therapeutics (HZNP) PT Raised to $118 at BMO Capital

February 24, 2021 5:34 PM EST
Get Alerts HZNP Hot Sheet
Price: $91.62 --0%

Rating Summary:
    15 Buy, 3 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 15 | Down: 6 | New: 26
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

BMO Capital analyst Gary Nachman raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $118.00 (from $115.00) while maintaining an Outperform rating.

The analyst commented, "4Q was very strong once again with Tepezza’s launch continuing to impress despite short-term supply disruption starting in Dec., and HZNP sounds confident in near-term resolution supported by robust 2021 guidance. Krystexxa's also recovering faster from COVID-19 with tailwinds from immunomodulation strategy; with that, 2021 guidance was solid as well. Viela deal should close by end-1Q, which meaningfully enhances HZNP's orphan portfolio and overall pipeline where investments are accelerating, and with several Ph2/3 programs that help further improve long-term outlook. We raised estimates; target to $118 from $115. Reiterate Outperform."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

BMO Capital